Source: International Congress 2018 – CC7 Severe asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Drijver-Messelink (Groningen, Netherlands). Eosinophilic otitis media and eosinophilic asthma; shared pathophysiology and response to anti-IL5. International Congress 2018 – CC7 Severe asthma

Member's Comments

No comment yet.

Related content which might interest you: Eosinophilic inflammation and asthma control Source: Annual Congress 2009 - Inflammation and airways Year: 2009 Eosinophilic refractory inflammation in OCS-dependent severe asthma Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 Eosinophilic asthma Source: Eur Respir Monogr 2022; 95: 73-99 Year: 2022 Effect of optimized anti-inflammatory treatment in patients with asthma and eosinophilic otitis media Source: International Congress 2017 – Bronchial asthma management Year: 2017 Eosinophilic airway inflammation in COPD and asthma Source: Annual Congress 2008 - Invasive and noninvasive measurements of lung inflammation Year: 2008 Effect of anti-IL5 treatment on symptoms of chronic rhinosinusitis, otitis and hearing loss in patients with severe eosinophilic asthma Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 Clinical outcome of eosinophilic airway inflammation in chronic airway diseases including nonasthmatic eosinophilic bronchitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Idiopathic chronic eosinophilic pneumonia and asthma: how do they influence each other? Source: Eur Respir J 2003; 22: 8-13 Year: 2003 Novel treatment of eosinophilic bronchitis with allergic fungal sinusitis using mepolizumab Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017 The pathological feature of airway inflammation in eosinophilic bronchitis Source: Eur Respir J 2005; 26: Suppl. 49, 282s Year: 2005 Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Clinical implication of interleukin-33 in acute eosinophilic pneumonia compared with chronic eosinophilic pneumonia Source: Annual Congress 2011 - Biomarkers of allergic inflammation Year: 2011 Modulation of Eosinophilic airway inflammation in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 441s Year: 2005 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 The importance of eosinophilic inflammation in COPD exacerbations Source: International Congress 2017 – COPD management Year: 2017 Manifestation of idiopathic chronic eosinophilic pneumonia Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009 Idiopathic acute and chronic eosinophilic pneumonia Source: Annual Congress 2009 - Update on eosinophilic lung diseases Year: 2009 Neutrophilic inflammation in nasal lavage (NL) and induced sputum (IS) from patients with chronic sinusitis or chronic sinusitis and asthma Source: Eur Respir J 2003; 22: Suppl. 45, 455s Year: 2003 Diffuse idiopathic pulmonary neuroendocrine hyperplasia, chronic eosinophilic pneumonia, and asthma Source: Eur Respir J 2009; 34: 1489-1492 Year: 2009 Benralizumab for severe asthma associated with extra-airway eosinophilic diseases Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020